Ianalumab, a monoclonal antibody targeting anti-B cell activating factor (BAFF) receptor is currently being tested in a large multicenter, randomized, double-blind, placebo-controlled phase 2–3 clinical trial in AIH patients with incomplete response or intolerance to standard treatment (NCT03217422). This evidence concerns the gene TNFSF13B and autoimmune hepatitis.